消化性潰瘍治療薬市場規模、シェア、成長分析、薬剤タイプ別、潰瘍タイプ別、エンドユーザー別、地域別 - 産業予測、2025～2032年

消化性潰瘍治療薬市場規模は2023年に47億6,000万米ドルで、予測期間（2025-2032年）のCAGRは3.50%で、2024年の49億3,000万米ドルから2032年には64億9,000万米ドルに成長する見通しです。

世界の消化性潰瘍治療薬市場は、さまざまな促進要因に後押しされて上昇基調にあります。消化性潰瘍疾患は世界的に数百万人が罹患しており、この胃腸疾患の有病率の増加、高齢化人口の拡大、喫煙や飲酒などの不健康なライフスタイルの急増が市場を後押ししています。医療技術の進歩や革新的な製剤のイントロダクションが、市場の成長をさらに後押ししています。しかし、ジェネリック医薬品の利用可能性や代替治療法の台頭などの課題も存在します。しかし、早期診断と効果的な治療の重要性に対する意識の高まりは、こうした課題に直面しながらも継続的な成長を確保し、市場を前進させると予想されます。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

消化性潰瘍治療薬市場規模：薬剤タイプ別

• 市場概要
• プロトンポンプ阻害剤
• H2拮抗薬
• 抗生物質
• その他

消化性潰瘍治療薬市場規模：潰瘍タイプ別

• 市場概要
• 胃潰瘍
• 十二指腸潰瘍
• 食道潰瘍

消化性潰瘍治療薬市場規模：エンドユーザー別

• 市場概要
• 病院
• 小売薬局
• オンライン薬局

消化性潰瘍治療薬市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• AstraZeneca plc.（United Kingdom）
• Pfizer Inc.（United States）
• Novartis AG（Switzerland）
• Takeda Pharmaceutical Company Limited（Japan）
• GlaxoSmithKline plc.（United Kingdom）
• Sanofi S.A.（France）
• Johnson & Johnson（United States）
• Merck & Co., Inc.（United States）
• Bayer AG（Germany）
• AbbVie Inc.（United States）
• Eli Lilly and Company（United States）
• Daiichi Sankyo Company, Limited（Japan）
• Bristol-Myers Squibb Company（United States）
• Mylan N.V.（Netherlands）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Sun Pharmaceutical Industries Ltd.（India）
• Dr. Reddy's Laboratories Ltd.（India）
• Cipla Ltd.（India）
• Lupin Ltd.（India）
• Zydus Cadila（India）

結論と推奨事項

Peptic Ulcer Drugs Market size was valued at USD 4.76 Billion in 2023 and is poised to grow from USD 4.93 Billion in 2024 to USD 6.49 Billion by 2032, growing at a CAGR of 3.50% during the forecast period (2025-2032).

The global peptic ulcer drugs market is on an upward trajectory, fueled by various driving factors. With millions affected by peptic ulcer disease globally, the market is bolstered by the increasing prevalence of this gastrointestinal disorder, an expanding aging population, and a surge in unhealthy lifestyle choices like smoking and alcohol use. Technological advancements in medicine and the introduction of innovative drug formulations further enhance market growth. However, challenges exist, including the availability of generic drugs and the rise of alternative treatment options. Nonetheless, heightened awareness around the significance of early diagnosis and effective treatment is anticipated to propel the market forward, ensuring continued growth in the face of these challenges.

Top-down and bottom-up approaches were used to estimate and validate the size of the Peptic Ulcer Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Peptic Ulcer Drugs Market Segmental Analysis

Global Peptic Ulcer Drugs Market is segmented by drug type, ulcer type, end user and region. Based on drug type, the market is segmented into proton pump inhibitors, H2 antagonists, antibiotics and others. Based on ulcer type, the market is segmented into gastric ulcer, duodenal ulcer and esophageal ulcer. Based on end user, the market is segmented into hospitals, retail pharmacies and online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Peptic Ulcer Drugs Market

The global peptic ulcer drugs market is significantly driven by the rising prevalence of peptic ulcers across the globe. This common gastrointestinal condition impacts millions, creating a heightened demand for effective treatment alternatives. Contributing factors such as unhealthy lifestyles, increased stress levels, and the regular use of non-steroidal anti-inflammatory drugs (NSAIDs) are fueling the surge in peptic ulcer cases. As a result, there is a continued push for innovative and effective medications, fostering overall growth in the market. This increasing incidence emphasizes the urgent need for solutions, making the peptic ulcer drugs market an area of considerable focus and expansion.

Restraints in the Peptic Ulcer Drugs Market

The global peptic ulcer drugs market faces restraint due to the presence of various alternative treatment options. Beyond conventional pharmaceutical interventions, patients often have access to non-pharmacological methods, such as lifestyle alterations, dietary adjustments, and natural remedies, which are perceived as effective alternatives for managing peptic ulcers. This preference for non-drug approaches can significantly diminish the demand for traditional medications. Additionally, concerns regarding the potential side effects and long-term risks associated with the use of peptic ulcer drugs may further deter patients and healthcare providers, thereby affecting overall market dynamics and growth potential.

Market Trends of the Peptic Ulcer Drugs Market

A prominent market trend in the global peptic ulcer drugs sector is the rising preference for proton pump inhibitors (PPIs) as the primary treatment choice. This shift is fueled by the efficacy and safety of PPIs, which outperform other medication classes in reducing stomach acid production and providing lasting relief from ulcer symptoms. Enhanced drug formulations have further increased the bioavailability and compliance of PPIs in patients, making them more appealing. Such factors are contributing to a robust demand for these medications, positioning PPIs as a cornerstone in peptic ulcer therapies and fostering growth within the overall market landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Peptic Ulcer Drugs Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Proton Pump Inhibitors
• H2 Antagonists
• Antibiotics
• Others

Global Peptic Ulcer Drugs Market Size by Ulcer Type & CAGR (2025-2032)

• Market Overview
• Gastric Ulcer
• Duodenal Ulcer
• Esophageal Ulcer

Global Peptic Ulcer Drugs Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Retail Pharmacies
• Online Pharmacies

Global Peptic Ulcer Drugs Market Size & CAGR (2025-2032)

• North America (Drug Type, Ulcer Type, End User)
  • US
  • Canada
• Europe (Drug Type, Ulcer Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Ulcer Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Ulcer Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Ulcer Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AstraZeneca plc. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations